Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate Proteomics in Type 2 Diabetes
NCT03829514Phase 4Completed
- Sponsor
- Medical University of South Carolina
- Start
- Feb 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fenofibrate in type 2 diabetes mellitus (T2DM), sponsored by Medical University of South Carolina. Primary endpoint: Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid Chromatography-mass Spectrometry at 6 weeks. Started Feb 2019; status: completed.
02
Drugs
fenofibrate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03829514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829514.